journal
MENU ▼
Read by QxMD icon Read
search

Journal of the Neurological Sciences

journal
https://www.readbyqxmd.com/read/29691044/symptomatic-orthostatic-hypotension-in-parkinson-s-disease-patients-prevalence-associated-factors-and-its-impact-on-balance-confidence
#1
LETTER
(no author information available yet)
No abstract text is available yet for this article.
April 12, 2018: Journal of the Neurological Sciences
https://www.readbyqxmd.com/read/29678331/risk-factors-of-symptomatic-orthostatic-hypotension-patients-with-parkinson-s-disease
#2
LETTER
Tomoyuki Kawada
No abstract text is available yet for this article.
April 11, 2018: Journal of the Neurological Sciences
https://www.readbyqxmd.com/read/29559176/does-istradefylline-really-have-a-dystonic-mechanism
#3
LETTER
Hiroshi Kataoka, Kazuma Sugie
No abstract text is available yet for this article.
March 14, 2018: Journal of the Neurological Sciences
https://www.readbyqxmd.com/read/29555107/authors-reply-to-the-comments-of-kataoka-et-al-regarding-could-istradefylline-be-a-treatment-option-for-postural-abnormalities-in-mid-stage-parkinson-s-disease
#4
LETTER
Keisuke Suzuki, Tomoyuki Miyamoto, Masayuki Miyamoto, Tomoyuki Uchiyama, Koichi Hirata
No abstract text is available yet for this article.
March 14, 2018: Journal of the Neurological Sciences
https://www.readbyqxmd.com/read/29519687/reprint-of-clinical-management-of-tardive-dyskinesia-five-steps-to-success
#5
REVIEW
Leslie Citrome
Tardive dyskinesia (TD) has long been thought to be a generally irreversible consequence of the use of dopamine receptor blocking agents. There is now an opportunity to successfully manage this condition with agents approved by the US Food and Drug Administration. This is important because TD has not been eliminated with the use of second-generation antipsychotics, and the expansion of antipsychotics to treat conditions other than schizophrenia has resulted in millions of additional individuals at risk for developing TD...
June 15, 2018: Journal of the Neurological Sciences
https://www.readbyqxmd.com/read/29506749/tardive-syndromes
#6
REVIEW
Daniel Savitt, Joseph Jankovic
Tardive syndromes are a group of hyperkinetic and hypokinetic movement disorders that occur after some delay following exposure to dopamine receptor blocking agents such as antipsychotic and anti-emetic drugs. The severity of these disorders ranges from mild to disabling or even life-threatening. There is a wide range of recognized tardive phenomenologies that may occur in isolation or in combination with each other. These phenomenologies include stereotypy, dystonia, chorea, akathisia, myoclonus, tremor, tics, gait disorders, parkinsonism, ocular deviations, respiratory dyskinesia, and a variety of sensory symptoms...
June 15, 2018: Journal of the Neurological Sciences
https://www.readbyqxmd.com/read/29502799/genetics-of-tardive-dyskinesia-promising-leads-and-ways-forward
#7
REVIEW
Clement C Zai, Miriam S Maes, Arun K Tiwari, Gwyneth C Zai, Gary Remington, James L Kennedy
Tardive dyskinesia (TD) is a potentially irreversible and often debilitating movement disorder secondary to chronic use of dopamine receptor blocking medications. Genetic factors have been implicated in the etiology of TD. We therefore have reviewed the most promising genes associated with TD, including DRD2, DRD3, VMAT2, HSPG2, HTR2A, HTR2C, and SOD2. In addition, we present evidence supporting a role for these genes from preclinical models of TD. The current understanding of the etiogenesis of TD is discussed in the light of the recent approvals of valbenazine and deutetrabenazine, VMAT2 inhibitors, for treating TD...
June 15, 2018: Journal of the Neurological Sciences
https://www.readbyqxmd.com/read/29454494/historical-perspectives-on-tardive-dyskinesia
#8
REVIEW
Stanley N Caroff, Gabor S Ungvari, David G Cunningham Owens
Tardive dyskinesia (TD) is a persistent hyperkinetic movement disorder associated with dopamine receptor blocking agents including antipsychotic medications. Although uncertainty and concern about this drug side effect have vacillated since its initial recognition 60 years ago, recent commercial interest in developing effective treatments has rekindled scientific and clinical interest after a protracted period of neglect. Although substantial research has advanced knowledge of the clinical features and epidemiology of TD, many fundamental questions raised by early investigators remain unresolved...
June 15, 2018: Journal of the Neurological Sciences
https://www.readbyqxmd.com/read/29454493/updating-the-recommendations-for-treatment-of-tardive-syndromes-a-systematic-review-of-new-evidence-and-practical-treatment-algorithm
#9
REVIEW
Roongroj Bhidayasiri, Onanong Jitkritsadakul, Joseph H Friedman, Stanley Fahn
BACKGROUND: Management of tardive syndromes (TS) is challenging, with only a few evidence-based therapeutic algorithms reported in the American Academy of Neurology (AAN) guideline in 2013. OBJECTIVE: To update the evidence-based recommendations and provide a practical treatment algorithm for management of TS by addressing 5 questions: 1) Is withdrawal of dopamine receptor blocking agents (DRBAs) an effective TS treatment? 2) Does switching from typical to atypical DRBAs reduce TS symptoms? 3) What is the efficacy of pharmacologic agents in treating TS? 4) Do patients with TS benefit from chemodenervation with botulinum toxin? 5) Do patients with TS benefit from surgical therapy? METHODS: Systematic reviews were conducted by searching PsycINFO, Ovid MEDLINE, PubMed, EMBASE, Web of Science and Cochrane for articles published between 2012 and 2017 to identify new evidence published after the 2013 AAN guidelines...
June 15, 2018: Journal of the Neurological Sciences
https://www.readbyqxmd.com/read/29449008/tardive-dyskinesia-out-of-the-shadows
#10
REVIEW
Robert A Hauser, Daniel Truong
The approvals of the first two medications, valbenazine and deutetrabenazine, to treat tardive dyskinesia have ushered in a new era in neuropsychiatric care. Tardive syndromes are defined as delayed onset, persistent movement disorders or sensory phenomena that occur in association with exposure to dopamine receptor blocking agents (DRBAs). Their underlying pathophysiology remains to be fully elucidated, but clinicians can conceptualize tardive syndromes as persistent dopamine supersensitivity states. Tardive syndromes can potentially cause distress, disfigurement, embarrassment, and dysfunction, and are often permanent...
June 15, 2018: Journal of the Neurological Sciences
https://www.readbyqxmd.com/read/29439776/clinical-risk-factors-for-the-development-of-tardive-dyskinesia
#11
REVIEW
Marco Solmi, Giorgio Pigato, John M Kane, Christoph U Correll
BACKGROUND: Tardive dyskinesia (TD) is a severe condition that can affect almost 1 out of 4 patients on current or previous antipsychotic treatment, including both first-generation antipsychotics (FGAs) and second-generation antipsychotics (SGAs). While two novel vesicular monoamine transporter inhibitors, deutetrabenazine and valbenazine, have shown acute efficacy for TD, the majority of patients do not remit, and TD appears to recur once treatment is withdrawn. Hence, prevention of TD remains a crucial goal...
June 15, 2018: Journal of the Neurological Sciences
https://www.readbyqxmd.com/read/29433811/tardive-dyskinesia-epidemiology
#12
REVIEW
Anelyssa D'Abreu, Umer Akbar, Joseph H Friedman
The term tardive syndrome (TS) encompasses a few different phenomenologic conditions, some of which occur in isolation and others in association with each other. This, along with the unusual confound for a drug side effect, in which increased use of the drug improves the problem, and the need for most patients to continue taking the offending drug, makes understanding the epidemiology difficult and unreliable. While the change from the "first generation" to the "second generation" of antipsychotic drugs is generally believed to have reduced the incidence of TS, prospective research studies have not supported that contention...
June 15, 2018: Journal of the Neurological Sciences
https://www.readbyqxmd.com/read/29433810/the-nosology-of-tardive-syndromes
#13
Karen Frei, Daniel D Truong, Stanley Fahn, Joseph Jankovic, Robert A Hauser
Since the original description of side effects of neuroleptics, different terminologies and definitions for tardive dyskinesia (TD) and tardive syndrome (TS) have been used by different authors, and often these two terms have been used interchangeably. This paper proposes a nosology designed to define and clarify various terms and phenomenologies within the TS spectrum. We propose to use the term tardive dyskinesia to refer to the original description of repetitive and complex oral-buccal-lingual (OBL) movements, as well as to the analogous repetitive movements that can appear in the limbs, trunk, or pelvis...
June 15, 2018: Journal of the Neurological Sciences
https://www.readbyqxmd.com/read/29433809/future-directions-in-tardive-dyskinesia-research
#14
REVIEW
Jonathan M Meyer
Tardive dyskinesia (TD) research is at a crossroads because of renewed interest in this syndrome following the successful development and regulatory approval of two novel vesicular monoamine transport 2 (VMAT2) inhibitors. Despite these clinical advances, significant lacunae exist in the knowledge base of TD pathophysiology, prognosis, and epidemiology. Moreover, conflicting definitions of TD as either a syndrome that encompasses a broad array of related phenomena or as a specific subset of tardive syndromes are an impediment to both clinical and basic science research, and to educational efforts targeting nonspecialist clinicians...
June 15, 2018: Journal of the Neurological Sciences
https://www.readbyqxmd.com/read/29433808/vmat2-inhibitors-for-the-treatment-of-tardive-dyskinesia
#15
REVIEW
Laura M Scorr, Stewart A Factor
Tardive dyskinesia (TD) is an often disabling hyperkinetic movement disorder caused by exposure to dopamine receptor blocking agents. Although initially thought to most commonly occur with typical antipsychotics, the incidence is likely similar with atypical antipsychotics and antiemetics such as metoclopramide. Increased prescribing of these agents as well as low rates of remission have contributed to a rising prevalence of TD. Although this condition was described nearly 60 years ago, it is only within the past year that two novel therapeutic agents were FDA approved...
June 15, 2018: Journal of the Neurological Sciences
https://www.readbyqxmd.com/read/29433807/deep-brain-stimulation-for-tardive-syndromes-systematic-review-and-meta-analysis
#16
REVIEW
Antonella Macerollo, Günther Deuschl
Among the broad entity of tardive syndromes, tardive dystonia and classical tardive dyskinesia sometimes require advanced treatments like deep brain stimulation of the globus pallidus internum (Gpi-DBS) or the subthalamic nucleus (STN-DBS). This systematic review has analyzed the currently available literature reporting cases with either tardive dystonia or dyskinesia treated with DBS. The key words for the literature search included all tardive syndromes and "deep brain stimulation." Thirty-four level VI studies and one level II study with 117 patients were included...
June 15, 2018: Journal of the Neurological Sciences
https://www.readbyqxmd.com/read/29433806/non-vmat2-inhibitor-treatments-for-the-treatment-of-tardive-dyskinesia
#17
REVIEW
Chih-Chun Lin, William G Ondo
Although VMAT2-inhibitors are now established as first-line treatment for tardive dyskinesia, not all patients respond to, or tolerate them. Numerous other agents have been adopted to treat tardive dyskinesia, but with variable results and generally lower quality methodologic reports. Amantadine is the most promising but benzodiazepines, branched chain neutral amino acids, Vitamin B6, several nutraceuticals, and botulinum toxin injections might help some patients. In all cases, better placebo controlled trials are needed before definitive recommendations can be made...
June 15, 2018: Journal of the Neurological Sciences
https://www.readbyqxmd.com/read/29627040/insulin-resistance-and-cognitive-test-performance-in-elderly-adults-national-health-and-nutrition-examination-survey-nhanes
#18
Ayesha Z Sherzai, Magda Shaheen, Jeffrey J Yu, Konrad Talbot, Dean Sherzai
OBJECTIVES: To examine the relationship between homeostatic model of insulin resistance (HOMA-IR) and cognitive test performance among population≥60years in a national database. HYPOTHESIS: Higher insulin resistance is associated with lower cognitive test performance score in the population≥60years. PARTICIPANTS: We analyzed data from the National Health and Nutrition Examination Survey (NHANES) 1999-2000 and 2001-2002. MEASUREMENTS: Cognitive test performance was measured by the Digit Symbol Substitution (DSS) exercise score...
May 15, 2018: Journal of the Neurological Sciences
https://www.readbyqxmd.com/read/29627039/peripheral-nervous-system-involvement-in-leber-s-hereditary-optic-neuropathy
#19
LETTER
Jonathan Ciron, Clément Baron, Michèle Boissonnot, Jean-Philippe Neau, Corinne Magdelaine, Jean-Michel Vallat, Stéphane Mathis
No abstract text is available yet for this article.
May 15, 2018: Journal of the Neurological Sciences
https://www.readbyqxmd.com/read/29627038/combining-clinical-and-magnetic-resonance-imaging-markers-enhances-prediction-of-12-year-employment-status-in-multiple-sclerosis-patients
#20
Lucie Kadrnozkova, Manuela Vaneckova, Lukas Sobisek, Barbora Benova, Karolina Kucerova, Jiri Motyl, Michaela Andelova, Klara Novotna, Jana Lizrova Preiningerova, Jan Krasensky, Eva Havrdova, Dana Horakova, Tomas Uher
BACKGROUND: Multiple sclerosis (MS) is frequently diagnosed in the most productive years of adulthood and is often associated with worsening employment status. However, reliable predictors of employment status change are lacking. OBJECTIVE: To identify early clinical and brain magnetic resonance imaging (MRI) markers of employment status worsening in MS patients at 12-year follow-up. METHODS: A total of 145 patients with early relapsing-remitting MS from the original Avonex-Steroids-Azathioprine (ASA) study were included in this prospective, longitudinal, observational cohort study...
May 15, 2018: Journal of the Neurological Sciences
journal
journal
23822
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"